2024 ASCO Annual Meeting: Black Diamond Therapeutics presents promising clinical data for BDTX-1535 in recurrent glioblastoma with favorable safety, tolerability, and anti-tumor activity.
Black Diamond Therapeutics presents promising clinical data for BDTX-1535 in patients with recurrent glioblastoma at the 2024 ASCO Annual Meeting. Phase 1 dose escalation trial shows favorable safety, tolerability, and anti-tumor activity. Initial data from a Phase 0/1 "trigger" investigator-sponsored trial indicates BDTX-1535 achieves clinically meaningful drug levels in brain tumor tissue.
June 01, 2024
4 Articles